Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd.

Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd.

June 17, 2016

Innovative Partnership of Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine Expands Focus to Include Antibody Drug Discovery Research

NEW YORK (June 16, 2016) and OSAKA, JAPAN, (June 17, 2016) ─ Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite early-stage drug discovery of innovative new therapies. Under this expansion, Tri-I TDI will extend its current relationship with its industry partner, Takeda Pharmaceutical Company, Ltd. (TSE:4502) from the realm of small molecule discovery into the new research area of antibody drug discovery. All three institutions will benefit from Tri-I TDI’s expansion.
“We are thrilled at the prospect of growing our strong Tri-I TDI partnership, where we continue to tackle important health questions and improve drug development efficiency. Through our current work, we’ve established a streamlined process to apply our breakthrough research into clinical application and look forward to adding antibody knowledge into our expanding range of capabilities” said Dr. Augustine Choi, interim dean of Weill Cornell Medicine.
“TDI has already had an important impact by providing an opportunity for our scientists, and those of our collaborating institutions, to develop small molecules that might lead to new drugs,” said Dr. Marc Tessier-Lavigne, president of The Rockefeller University. “With the addition of its antibody program, TDI will go even further, jumpstarting the development of an additional type of therapy for poorly treated diseases.”
“What began as a novel partnership between academia and industry has now become a powerful voice in medical research,” said Memorial Sloan Kettering President and CEO Dr. Craig B. Thompson. “Our collaboration has provided more efficient paths to translate laboratory discoveries into bedside treatments that lead to improved patient care and well being.  This partnership is a great example of how collaboration and open partnerships are the future of medical research.” 
“As we look ahead to what’s next, beyond small molecule drug discovery, this flagship collaboration will continue to push the boundaries of what’s possible in medical research,” said Andrew Plump, Takeda’s chief medical and scientific officer. “We at Takeda understand the value of, and connection between, innovation and external collaboration. This is why we are so pleased to continue our relationship with the Tri-I TDI and help expand its mission to move toward novel research frontiers such as antibody drug discovery.”

Tri-Institutional Therapeutics Discovery Institute
The independent nonprofit Tri-I TDI was launched in 2013, and has its own scientific advisory board and board of directors. The Tri-I TDI is located on the top floor of the new, state-of-the-art Belfer Research Building at Weill Cornell Medicine, and the new antibody facilities are housed in the Zuckerman Research Center at Memorial Sloan Kettering Cancer Center. Tri-I TDI was established to bridge the gap between groundbreaking early-stage academic research discoveries and the development of new diagnostic or therapeutic agents. Tri-I TDI supports translational research across the Tri-I community by leveraging the expertise of all three academic institutions and its industry partner, Takeda.
The organization’s initial and continuing goals are to foster discovery and translational research, to provide high-quality educational opportunities to all members of the Tri-I community, and to deepen faculty involvement in drug discovery. In the context of its expanding partnership with Takeda, Tri-I TDI will explore new areas where it can provide value to patients. As innovation and technology take center stage in the conversation around the future of healthcare, the new antibody drug discovery initiative – which many consider a frontier in the health industry – is a clear and inspiring direction in which to take the institute.
As Tri-I TDI’s sole industry partner, Takeda contributes a team of experienced chemists and pharmacologists, along with a wealth of institutional knowledge and best practices gained from its position as an established industry leader in the pharmaceutical sector.
Philanthropy is helping to drive discoveries at the Tri-I TDI. The three institutions received an initial $15 million gift from Lewis and Ali Sanders to launch the Tri-I TDI and, recently, a second $15 million gift from the couple to grow its mission. The institute is also funded through direct contributions from Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine. An important aspect of the institute continues to be the Sanders Innovation and Education Initiative, which lends organizational infrastructure, project management, director salary support, education for a new generation of drug discovery scientists, and in-lab support of faculty to drive the institute’s innovative mission.

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering (MSK) is the world’s oldest and largest private cancer center, home to more than 14,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, MSK combines 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And MSK's always-evolving educational programs continue to train new leaders in the field, both at MSK and around the world. For more information, go to

The Rockefeller University
The Rockefeller University is the world’s leading biomedical research university and is dedicated to conducting innovative, high-quality research to improve the understanding of life for the benefit of humanity. Its 79 laboratories conduct research in neuroscience, immunology, biochemistry, genomics and many other areas, and a community of over 2,000 faculty, students, postdocs, technicians, clinicians and administrative personnel work on a 14-acre Manhattan campus. Rockefeller’s unique approach to science has led to some of the world’s most revolutionary and transformative contributions to biology and medicine. During Rockefeller’s 115-year history, 24 of our scientists have won Nobel Prizes, 21 have won Albert Lasker Medical Research Awards and 20 have garnered the National Medal of Science, the highest science award given by the United States.

Weill Cornell Medicine
Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. The doctors and scientists of Weill Cornell Medicine — faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization — are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side's scientific corridor, Weill Cornell Medicine’s powerful network of collaborators extends to its parent university Cornell University; to Qatar, where an international campus offers a U.S. medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey. Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Lower Manhattan Hospital and NewYork-Presbyterian/Queens. Weill Cornell Medicine is also affiliated with Houston Methodist. For more information, visit

TakedaPharmaceutical Company, Ltd.
Takeda Pharmaceutical Company, Ltd. is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases, as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, go to